胰岛素样生长因子2 mRNA结合蛋白3（IGF2BP3）在子宫内膜癌中上调，并通过高迁移率族蛋白A1（HMGA1）紧密调节耐药子宫内膜癌细胞的生长。

IGF2BP3 is upregulated in endometrial cancer and tightly regulates the growth of drug-resistant endometrial cancer cells via HMGA1.

作者信息

Zhang Yiwei, Xiao Yanlai, Zhao Xiangzhai, Xu Jie, Zhao Huan, Guo Zhaojun, Zhao Jun, Zhang Yajing, Wang Ruoxi, Wang Jian

机构信息

Department of Obstetrics and Gynecology, Hebei Medical University Third Hospital, Shijiazhuang, China.

出版信息

Sci Prog. 2025 Jan-Mar;108(1):368504251315008. doi: 10.1177/00368504251315008.

DOI:10.1177/00368504251315008

PMID:39878052

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11775961/

Abstract

OBJECTIVE

Endometrial cancer (EC) is a malignant tumor with various histological subtypes and molecular phenotypes. The evaluation of drug resistance is important for cancer treatment. Progesterone resistance is the major challenge in EC. Knowledge of drug resistance in EC is important in the development of novel therapies.

METHODS

In this study, ten paracancerous and ten tumor tissues were collected to measure the expression of insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) and high-mobility group protein 1 (HMGA1). AN3CA and Ishikawa cells were used to explore the effects of IGF2BP3 on EC.

RESULTS

The expression levels of IGF2BP3 and HMGA1 were higher in EC tumor tissues than in paracancerous tissues. IGF2BP3 and HMGA1 are highly expressed in cisplatin-resistant EC cells. IGF2BP3 knockdown decreased the growth of cisplatin-resistant EC cells. Knockdown of IGF2BP3 decreased the level of HMGA1 protein. HMGA1 knockdown decreased the growth of cisplatin-resistant EC cells.

DISCUSS AND CONCLUSIONS

The findings demonstrate that IGF2BP3 is upregulated in EC and closely regulates the growth of drug-resistant EC cells via HMGA1. The findings will inform the development of novel therapies for EC.

摘要